Get drug firms out of drug approval

By: 

Michael Kennedy, PhD
Jan 15, 2008

In a commentary for APM's Marketplace, Dr. Stefan Kertesz questions the current process of approving new drugs, especially when researchers who set health care guidelines also have financial interests in pharmaceutical companies. He cites the timing  of the National Cholesterol Education Panel's announcement on recommended cholesterol levels and the drug Vytorin's release to illustrate the need for reform. 

Original Article

Topic: 

  • Share/Save

Add new comment

More information about text formats

Filtered HTML

  • Web page addresses and e-mail addresses turn into links automatically.
  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd> <p> <div> <br> <sup> <sub>
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

More like this

Helix Magazine

is a publication by Science in Society, a Northwestern University research center for science outreach and public engagement.

Follow Us

SiS Initiatives

Mather Science Explorers

Mather Science Explorers pairs scientists (Science Education Fellows) with small groups of freshmen biology students to help students build science skills and achieve academic success in the transition to high school.

Support and training includes:

  • A focus on long-term academic relationships. Fellows meet with...
MORE INITIATIVES